HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

John Xie Selected Research

Body Weight (Weight, Body)

11/2017Canagliflozin in Conjunction With Sulfonylurea Maintains Glycemic Control and Weight Loss Over 52 Weeks: A Randomized, Controlled Trial in Patients With Type 2 Diabetes Mellitus.
12/2016Canagliflozin: Efficacy and Safety in Combination with Metformin Alone or with Other Antihyperglycemic Agents in Type 2 Diabetes.
5/2016Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks.
5/2016Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from India.
1/2016The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus.
6/2015Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes.
3/2015Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


John Xie Research Topics

Disease

12Type 2 Diabetes Mellitus (MODY)
12/2017 - 09/2013
7Body Weight (Weight, Body)
11/2017 - 03/2015
6Infections
11/2017 - 09/2013
4Weight Loss (Weight Reduction)
11/2017 - 06/2015
4Hypoglycemia (Reactive Hypoglycemia)
11/2017 - 03/2015
4Urinary Tract Infections (Urinary Tract Infection)
01/2017 - 09/2013
3Neoplasms (Cancer)
12/2007 - 07/2006
2Anemia
12/2007 - 07/2006
1Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
10/2021
1B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
01/2021
1Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome)
08/2020
1Thymoma (Thymic Carcinoma)
03/2020
1Syncope (Fainting)
03/2020
1Renal Insufficiency (Renal Failure)
10/2019
1Hyperuricemia
10/2019
1Chronic Kidney Failure (Chronic Renal Failure)
12/2017
1Kidney Diseases (Kidney Disease)
12/2017
1Albuminuria
12/2017
1Acute Kidney Injury (Acute Renal Failure)
01/2017
1Bone Resorption
01/2016
1Polyuria
09/2013
1Retinal Degeneration
05/2012

Drug/Important Bio-Agent (IBA)

12CanagliflozinIBA
12/2017 - 09/2013
10Glucose (Dextrose)FDA LinkGeneric
11/2017 - 05/2012
8SodiumIBA
11/2017 - 09/2014
8SymportersIBA
11/2017 - 09/2014
5Sodium-Glucose Transporter 2 InhibitorsIBA
01/2017 - 09/2013
4glimepiride (Amarel)FDA LinkGeneric
01/2017 - 09/2013
3Metformin (Glucophage)FDA LinkGeneric
12/2016 - 09/2013
3Epoetin Alfa (Epogen)FDA Link
12/2007 - 07/2006
3Hemoglobins (Hemoglobin)IBA
12/2007 - 07/2006
2CreatinineIBA
10/2019 - 12/2017
2Sodium-Glucose Transport ProteinsIBA
03/2015 - 09/2013
1amivantamab-vmjwIBA
10/2021
1ErbB Receptors (EGF Receptor)IBA
10/2021
1PlatinumIBA
10/2021
1Tyrosine Kinase InhibitorsIBA
10/2021
1ibrutinibIBA
01/2021
1Uric Acid (Urate)IBA
10/2019
1AlbuminsIBA
12/2017
1Pharmaceutical PreparationsIBA
11/2017
1empagliflozinIBA
01/2017
1dapagliflozinIBA
01/2017
1Hypoglycemic Agents (Hypoglycemics)IBA
12/2016
1Insulin (Novolin)FDA Link
12/2016
1MineralsIBA
01/2016
1OsteocalcinIBA
01/2016
1CollagenIBA
01/2016
1Blood Glucose (Blood Sugar)IBA
01/2016
1ElectrolytesIBA
09/2014
1Inosine Diphosphate (IDP)IBA
12/2007

Therapy/Procedure

5Drug Therapy (Chemotherapy)
10/2021 - 07/2006
3Glycemic Control
11/2017 - 05/2016
1Artificial Respiration (Mechanical Ventilation)
08/2020
1Therapeutics
12/2016